Rhythm Biosciences (ASX:RHY) share price roars 8% on new cancer markets

The company is looking to launch into new markets.

| More on:
man jumping along increasing bar graph signifying jump in alumina share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the move today. This comes after the company revealed its intentions to expand ColoSTAT into new cancer markets.

At the time of writing, the medical device company's shares are trading for $1.75 cents, up 4.79%.

What's driving the Rhythm share price higher?

Investors are fighting to get a hold of Rhythm shares after digesting the company's encouraging announcement.

According to the release, Rhythm advised that it has identified five new cancer detection markets to expand its platform technology.

As such, ColoSTAT is believed to hold multi-cancer detection properties, which could provide a foundation to expand the platform. Cancer markets include breast, cervical, lung, gastric, and pancreatic.

Rhythm's ColoSTAT is an experimental test kit that is being trialled as a low-cost, easy-to-use blood test to detect colorectal cancer.

It is estimated that around 850,000 people lose their life from colorectal cancer each year. In the United States, Europe, and Australia, over 130 million people aged between 50-74 years are unscreened for colorectal cancer. This represents an addressable market opportunity of more than $6.5 billion.

The strategic plan to expand the technological platform will form part of a research and development program. This is expected to follow a similar commercial pathway as to ColoSTAT.

The program will have access to $0.75 million worth of funds sourced from the company's last capital raising. In addition, the program could be eligible for the government R&D tax incentive rebate as well as other grants.

Rhythm CEO and managing director, Glenn Gilbert commented:

As we move closer to the launch of our initial cancer detection product ColoSTAT in 2022, the Company is making positive progress with respect to its broader strategy to leverage our cancer detection technology into other global cancer markets. Ultimately, Rhythm believes it can make a meaningful impact for improved health outcomes across millions of people around the world.

More on the Rhythm share price

The Rhythm share price has accelerated by 110% in the past 12 months, reflecting positive investor sentiment. Additionally, the company's shares reached an all-time high of $2.08 last month, before treading slightly lower.

At today's prices, Rhythm presides a market capitalisation of roughly $365.54 million, with approximately 208.88 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »